Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide written informed consent to participate in the study~* Willing and able to comply with all study requirements and instructions of the site study staff~* Male or female, 40 years to 85 years old (inclusive)~* Must be ambulatory~* Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of osteoarthritis (OA) and supported by radiological evidence Kellgren Lawrence Grade II to IV) that is not older than 6 months prior to the date of screening~* Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at screening~* Moderate to moderately-severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks prior to screening, have been/are being used)~* No analgesia (including acetaminophen \[paracetamol\]) taken 12 hours prior to an efficacy measure~* No known clinically significant liver abnormality e.g. cirrhosis, transplant, etc.)~Exclusion Criteria:~* As a result of medical review and screening investigation, the Principal Investigator considers the patient unfit for the study~* A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)~* A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)~* Presence of tense effusions~* Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator~* Isolated patella femoral syndrome, also known as chondromalacia~* Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial e.g. cancer, congenital defects, spine OA)~* Major injury to the index knee within the 12 months prior to screening~* Severe hip OA ipsilateral to the index knee~* Any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)~* Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study~* Use of the following medications:~  1. No IA injected pain medications in the study knee during the study~ 2. No analgesics containing opioids. NSAIDs may be continued at levels preceding the study and acetaminophen is available as a rescue medication during the study from the provided supply~ 3. No topical treatment on osteoarthritis index knee during the study~ 4. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as Aspirin and Plavix are allowed)~ 5. No systemic treatments that may interfere with safety or efficacy assessments during the study~ 6. No immunosuppressants~ 7. No use of corticosteroids \> 10 mg prednisolone equivalent per day (if ≤ 10 mg prednisolone, the dose must be stable)~* Any human albumin treatment in the 3 months before randomization

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ampion 4 mL Dose (Type: EXPERIMENTAL): 4 mL Injection of Ampion
- Placebo 4 mL Dose (Type: PLACEBO_COMPARATOR): 4 mL Injection of Placebo
- Ampion 10 mL Dose (Type: EXPERIMENTAL): 10 mL Injection of Ampion
- Placebo 10 mL Dose (Type: PLACEBO_COMPARATOR): 10 mL Injection of Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).